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Abstract
Backgrounds: The investigation of the environmental contribution for developmental neurotoxicity is very
important. Many environmental chemical exposures are now thought to contribute to the development of
neurological disorders, especially in children. Results from animal studies may guide investigations of human
populations toward identifying environmental contaminants and drugs that produce or protect from neurotoxicity
and may help in the treatment of neurodevelopmental disorders.
Objective: To study the protective effects of omega-3 polyunsaturated fatty acid on brain intoxication induced by
propionic acid (PPA) in rats.
Methods: 24 young male Western Albino rats were enrolled in the present study. They were grouped into three
equal groups; oral buffered PPA-treated group given a nuerotoxic dose of 250 mg/Kg body weight/day for 3 days;
omega-3 - protected group given a dose of 100 mg/kg body weight/day omega-3 orally daily for 5 days followed
by PPA for 3 days, and a third group as control given only phosphate buffered saline. Tumor necrosis factor-a,
caspase-3, interlukin-6, gamma amino-buteric acid (GABA), serotonin, dopamine and phospholipids were then
assayed in the rats brain’s tissue of different groups.
Results: The obtained data showed that PPA caused multiple signs of brain toxicity as measured by depletion of
gamaaminobyteric acid (GABA), serotonin (5HT) and dopamine (DA) as three important neurotransmitters that
reflect brain function. A high significant increase of interlukin-6 (Il-6), tumor necrosis factor-a (TNF-a) as excellent
markers of proinflammation and caspase-3 as a proapotic marker were remarkably elevated in the intoxicated
group of rats. Moreover, brain phospholipid profile was impaired in PPA-treated young rats recording lower levels
of phosphatidylethanolamine (PE), phosphatidylserine (PS) and phosphatidylcholine (PC).
Conclusions: Omega-3 fatty acids showed a protective effects on PPA - induced changes in rats as there was a
remarkable amelioration of most of the measured parameters (i.e. higher GABA, 5HT, DA, PE, PS and PC) and lower
Il-6, TNF-a and caspase-3.
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Introduction
There are several reasons to study and test environmen-
tal exposures for developmental neurotoxicity: [1] Five
thousand new chemicals are produced each year, and
according to estimates by the Environmental Protection
Agency, about 25% of them may be neurotoxic, but only
10% of them will ever be tested for neurotoxicity [2].
The developing brain is highly vulnerable and more sus-
ceptible to neurotoxic insults than is the adult brain [3].
Environmental chemical exposures are now thought to
contribute to the increases in attention deficit hyperac-
tivity disorder, cognitive problems, and autism spectrum
disorders that have been documented in the last 5-10
years [4]. Results from animal studies could be helpful
in identifying environmental toxins that related to neu-
rodevelopmental disorders as autism [1].
Neurotransmitters play unique trophic roles in brain
development. Accordingly, drugs and environmental
toxicants that promote or interfere with neurotransmit-
ter function evoke neurodevelopmental abnormalities by
disrupting the intensity of neuro trophic actions [2].
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highly unsaturated fatty acids (HUFAs) [3,4] and in con-
trast to other bodily tissue, a unique feature of neurons
is the smaller amounts of the precursors LA(18:2, n-6)
and ALA(18:3, n-3) and the higher amounts of their
metabolites: AA(20:4, n-6) and DHA(22:6, n-3) [3-5].
Propionic acid (PPA) is a weak organic acid that can
cross the lipid bilayer of neuronal membranes and cause
mild, reversible intracellular acidification, which can
produce wide spread effects on neurotransmitter release
involving glutamate, dopamine, and serotonin, each of
which can influence locomotion and other behaviors
[6-8].
Dependant mechanism may be important for effects of
P P Ao nb e h a v i o ro rc o g n i t i o n .I na d d i t i o n ,P P Ai s
thought to affect mitochondrial fatty acid metabolism by
binding to propionyl coenzyme A and by sequestering
carnitine [[9,10], El-Ansary A, Nounou H: On the effec-
tiveness of creatine and cyclosporine to protect against
propionic acid - induced neurotoxicity, submitted). Aut-
ism has been suggested to be a mitochondrial disorder
of impaired fatty acid metabolism [11,12]. Recently,
Macfabe et al (2011) [13] reported that rats treated with
PPA displayed some autistic features as restricted beha-
vioral interest to a specific object among a group of
objects, impaired social behavior, and impaired reversal
in a T-maze task compared to controls given phosphate
buffered saline. Moreover the reactive astrogliosis and
activated microglia, indicating an innate neuroinflamma-
tory response in PPA-treated rats.
Despite great efforts are directed towards the develop-
ment of effective treatment for autism, only few strate-
gies have been offered to autistics thus far. The
identification of an environmental risk factor related to
autism could help to develop a neuroprotective strategy
which could delay the onset of the disease. Several stu-
dies now recognize the central role of omega-3 polyun-
saturated fatty acids (n-3 PUFAs) in brain health.
Docosahexaenoic acid (DHA; 22:6n-3) is the most com-
mon n-3 PUFA within phospholipids of brain cell mem-
branes, while eicosapentaenoic acid (EPA; 20:5n-3) is
usually found in very limited amounts in the central
nervous system (CNS) [14,15]. The main dietary sources
of long chain PUFA, namely EPA and DHA, remain
fatty fish consumption. Besides their critical role in cell
membrane fluidity, PUFAs can be released from the
hydrophobic moiety of phospholipids via the enzyme
phospholipase A2 (PLA2) from which they can be soli-
cited in several intracellular events [16,17]. Although
specific mechanisms of action through which n-3
PUFAs act remain unknown, some pathways have been
suggested and studied in vitro as well as in vivo. These
include anti-inflammatory [18,19], anti-oxidant
[18,20,21] and anti-apoptotic properties [22].
This information initiates our interest to study the
neuroprotective effects of omega-3 on PPA-induced
neurotoxicity through the measurement of neurotrans-
mitters, cytokines, caspase-3 and phospholipids in con-
trol, PPA-treated and omega-3-protected-PPA
intoxicated rat pups.
Materials and methods
Animals
A total of 24 young male rats weighed about 45-60
(approximately 21 days old) were used in the present
study. Rats were randomly allocated to the following
groups. Oral buffered PPA-treated group given a nuero-
toxic dose of 250 mg/Kg body weight/day for 3 days as,
n = 8 [23] (omega-3 - protected group given a dose of
100 mg/kg body weight/day omega-3 orally daily for 5
days followed by PPA for 3 days, n = 8. A third group
of 8 rats were used as control given only phosphate buf-
fered saline. All groups were kept at controlled tempera-
ture (21 ± 1°C) with ad libtium access to food and
water. All experiments were performed in accordance
with national animal care guidelines and were pre-
approved by the faculty ethics committee, King Saud
University.
Tissue preparation
At the end of experiment, rats were anesthetized with
carbon dioxide. The brain was removed from the skull
and was cut into small pieces. Brain tissues of the three
groups of rats were homogenized in 10 times w/v bidis-
tilled water and were kept at -80°C until use.
Biochemical analyses
- Assay of tumor necrosis factor-a
Tumor necrosis factor -a was measured using ELISA
kit, a product of Hycult Biotech. The antibody reacts
with rat natural TNF -a and recognizes both membrane
and receptor bound. The TNF-a trimer interacts with
either of the two types of TNF-R leading to receptor
cross-linking. One unit of Hycult Biotech Mouse Tumor
Necrosis Factor -a approximates the bioactivity of 16
units of the human Tumor Necrosis factor -a standard
prepared by WHO as determined in L929 cytotoxic
assay.
- Assay of Caspase-3
Caspase-3 was measured using an ELISA kit, a product
of Cusabio. The microtiter plate provided in this kit has
been pre-coated with an antibody specific to Casp-3.
Standards or samples are then added to the appropriate
microtiter plate wells with a biotin-conjugated antibody
preparation specific for Casp-3 and Avidin conjugated
to Horseradish Peroxidase (HRP) is added to each
microplate well and incubated. Then a TMB (3,3’,5,5’
tetramethyl-benzidine) substrate solution is added to
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conjugated antibody and enzyme-conjugated Avidin will
exhibit a change in color. The enzyme-substrate reaction
is terminated by the addition of a sulphuric acid solu-
tion and the color change is measured spectrophotome-
trically at a wavelength of 450 nm ± 2 nm. The
concentration of Casp-3 in the samples is then deter-
mined by comparing the O.D. of the samples to the
standard curve.
- Assay of Interlukin-6
IL-6 was measured using an ELISA kit, a product of
Quantikine. A monoclonal antibody specific for rat IL-6
has been pre-coated onto a microplate. 50 μLo fS t a n -
dard, Control, or sample were placed in separate well.
The reagent was mixed by gently tapping the plate
frame for 1 minute after being covered with the adhe-
sive strip provided. The plate was incubated for 2 hours
at room temperature, any rat IL-6 present is bound by
the immobilized antibody. After washing away any
unbound substances, an enzyme-linked polyclonal anti-
body specific for rat IL-6 is added to the wells. Follow-
ing a wash to remove any unbound antibody-enzyme
reagent, 100 μL of Substrate Solution was added to each
well, and the plate was incubated for 30 minutes at
room temperature. The enzyme reaction yields a blue
product that turns yellow when the stop Solution is
added. The intensity of the color measured is in propor-
tion to the amount of rat IL-6 bound in the initial step.
The sample values are then read off the standard curve.
- Assay of Gamma amino-buteric acid (GABA)
Quantitative determination of GABA was done using
ELISA immunoassay kit, a product of ALPCO. 300 μL
of diluted standards, controls and undiluted samples
were placed into the appropriate wells of the extraction
Plate. 300 μL of the diluent was added to all wells, Cov-
ered with Adhesive foil and shakes for 30 min at RT
(20-25°C) on a shaker (600 rpm). Two washing cycles
were performed, after which 250 μl elution buffers was
placed into the appropriate wells of the extraction plate,
covered and shaked and then 100 μl of the extract was
used for subsequent derivatization. 10 μLo fN a O Hw a s
added into all wells followed by 50 μL of the equalizing
reagent (fresh prepared before assay) and shaked for 1
min on a shaker (600 rpm). 10 μL of the D-reagent was
added into all wells, incubated for 2 hours at (20-25°C)
and then 150 μL Q-buffer was added into all wells, incu-
bated for 10 min at RT (20-25°C) on a shaker (approx.
600 rpm). 25 μL of the derivatives then used for the
subsequent ELISA.
Assay of serotonin
Serotonin was measured using an ELISA kit, a product
of Immunology Biological Laboratories (IBL). Brain
homogenate preparation (derivatization of serotonin to
N-acylserotonin) is part of the sample dilution and is
achieved by incubation of the respective sample with the
Acylation Reagent. The assay procedure follows the
basic principle of competitive ELISA whereby there is
competition between a biotinylated and a non-biotiny-
lated antigen for a fixed number of antibody binding
sites. The amount of biotinylated antigen bound to the
antibody is inversely proportional to the N-acylserotonin
concentration of the sample. When the system is in
equilibrium, the free biotinylated antigen is removed by
a washing step and the antibody bound biotinylated
antigen is determined by use of anti-biotin alkaline
phosphatase as marker and p-nitrophenyl phosphate as
substrate. Quantification of unknowns is achieved by
comparing the enzymatic activity of unknowns with a
response curve prepared by using known standards.
-Dopamine assay
Dopamine was extracted by using a cis-diol-specific affi-
nity gel, acylated and then derivatized enzymatically.
Quantitavive assay was performed using ELISA kit, a
product of Immuno Biological Laboratories (IBL).
- Phospholipids Measurement
Briefly, 50 μl of brain homogenate was diluted with 750
μl deionized water followed by 2 ml of methanol and 1
ml of chloroform and was mixed well. The mixture was
stirred (Rotary mixture 34526, Snijders) for 15 min and
centrifuged for 5 min by 4000 rpm [24].
Phospholipid separation was performed on a Kaneur
Maxi Star HPLC system with four solvent lines, a degas-
ser SEDEX 55 evaporating light detector (SEDEX 55
Lichtstreu detector, S.E.D.E.E., France) which was
coupled with Apex M625 software (Autochrom, USA).
As the nebulizing gaz, N2 was used at a flow rate of 4l/
min, and a nebulizing temperature of 40°C. The gain
was set at 8 and 2.0 bar N2.
A 125 × 4.0 mm Si-60 column with 5 μm particle dia-
meter (Lichrosher) was used. The elution program was
a linear gradient with 80:19.5:0.5 (V/V) chloroform:
methanol: water: ammonia (NH3) at 22 min and the col-
umn was allowed to equilibrate until the next injection
at 27 min. The injection volume was 50 μl.
Statistical analysis
Computer SPSS program was used and results were
expressed as mean ± S.D. and all statistical comparisons
were made by means of the One-way ANOVA test
between the Control, PPA, omega-3+PPA groups and
Dunnett test as multiple comparisons. Reciever operat-
ing characteristics analysis was done. Area under the
curve (AUC), specificity and sensitivity were calculated.
Results and discussion
Typically an animal model is unlikely to replicate a
human disease [25]. The utility of such models relates
El-Ansary et al. Lipids in Health and Disease 2011, 10:142
http://www.lipidworld.com/content/10/1/142
Page 3 of 10to the various types of validity that can be shown to
exist for specific models. Evidence from human studies
suggests that autism is a condition that may involve an
ongoing neuroinflammatory disorder possibly resulting
from an increased sensitivity to oxidative stress from a
variety of environmental risk factors. The biochemical
finding of the present study model supports this
hypothesis.
Among the omega-3 PUFAs, docosahexaenoic acid
DHA is the most important ω3 with physiological signif-
icance for brain function [26,27], especially during pre-
natal brain development when it is incorporated into
nerve growth cones during synaptogenesis [28]. Studies
have shown that ω-3 dietary deficiency affect the gluta-
matergic, dopaminergic and serotoninergic systems
[29,30]. Glutamate is the main excitatory neurotransmit-
ter in the mammalian central nervous system (CNS),
involved in brain plastic processes, such as learning/
memory, brain development and ageing [31]. Hyperac-
tivity and anxiety-like behavior have been associated
with ω 3 deficiency in various animal models [32-36].
Table 1 demonstrates elevated levels of caspase3, IL-6
and TNF-a as three biochemical parameters related to
neuroinflammatory in PPA-treated rat pups. Increased
levels of these parameters could be easily correlated to
brain injury induced by PPA. On a molecular level, the
pro-inflammatory cytokines,T N F -a n dI L - 6 ,w h i c ha r e
produced by immune cells, display an increased expres-
sion in depression, multiple sclerosis and other neurolo-
gical disorders [37,38].
Table 1 also demonstrates the anti-apoptic effect of
omega-3 against the neurotoxic effect of PPA. Caspase 3
was significantly lower in protected animals compared
to unprotected PPA-treated rats. This are in good agree-
ment with the previous work of Suphioglu et al (2010)
[39] which reported a direct link between DHA treat-
ment and inhibition of apoptosis in M17 cells where
more than a 66% reduction in active caspase-3 protein
levels was detected in cells treated with 20 μg/ml DHA,
compared with the untreated cells. Investigations into
the mechanism of apoptotic cell death indicate that the
phosphatidylinositol 3-kinase/Akt signalling is a critical
pathway in this process and DHA acts in this pathway.
In cultured mouse neuroblastoma (Neuro 2A) cells,
DHA increased phosophatidyl serine levels resulting in
translocation and phosphorylation of Akt at Thr-308,
that suppressed activation of caspase-3 [40].
The anti-inflammatory effect of omega-3 reported in
the present study and demonstrated in table 1 and fig-
ure 1 as significant reduction in the levels of IL-6 and
TNF-a induced by PPA could be supported through
considering the previous reports of Song and Zhao
(2007) [41] on the use of omega-3 in treating
Table 1 Mean ± S.D of the measured parameters in
control, PPA-treated and Omega-3-protected groups.
Parameters Groups Min. Max. Mean ± S.D. P value
Control 110.34 125.50 119.37 ± 06.56
Caspase 3 PPA 137.97 172.31 154.44 ± 12.14
a 0.000
OMEGA 102.60 126.36 115.16 ± 07.80
Control 121.33 140.08 129.03 ± 8.06
IL6 PPA 129.34 159.37 143.52 ± 9.50
a 0.001
OMEGA 121.58 133.39 127.30 ± 4.33
Control 111.01 125.19 119.39 ± 6.10
TNF PPA 125.73 139.32 131.91 ± 4.38
a 0.000
OMEGA 135.17 146.29 139.01 ± 3.63
a
Control 95.42 105.03 100.45 ± 4.57
GABA PPA 71.58 90.63 079.09 ± 5.81
a 0.000
OMEGA 100.06 114.78 105.94 ± 5.15
Control 5.22 8.32 6.99 ± 1.30
Serotonin PPA 3.10 5.58 4.17 ± 0.85
a 0.000
OMEGA 6.02 9.00 7.01 ± 1.06
Control 15.37 19.98 17.91 ± 1.91
Dopamine PPA 6.88 17.63 12.56 ± 3.36
a 0.007
OMEGA 14.14 19.42 16.44 ± 1.83
Control 0.13 0.19 0.17 ± 0.03
PE PPA 0.05 0.11 0.09 ± 0.02
a 0.000
OMEGA 0.10 0.16 0.13 ± 0.02
a
Control 0.28 0.35 0.31 ± 0.03
PS PPA 0.06 0.18 0.12 ± 0.05
a 0.000
OMEGA 0.22 0.31 0.27 ± 0.03
Control 3.82 4.82 4.46 ± 0.46
PC PPA 1.05 2.74 1.97 ± 0.52
a 0.000
OMEGA 2.81 3.86 3.39 ± 0.32
a
￿ Significant levels between the three groups are illustrated as superscripts
letters when P < 0.05
Figure 1 P e r c e n t a g ec h a n g eo fc a s p a s - 3 ,I L 6 ,T N F - a,G A B A ,
serotonin and dopamine in PPA-treated and omega-3
protected groups compared to control.
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via their anti-inflammatory effect [42]. The mechanisms
include that omega-3 fatty acids decrease the production
of pro-inflammatory cytokines, such as TNF-a and IL-
1b [43] which have been implicated in the mechanism
that benefits neurogenesis and cell fate [44].
The remarkable induction of GABA, 5HT and dopa-
mine in rat brain treated with omega-3 as a neuropro-
tective supplement against PPA neurotoxicity, could
find a support through considering the work of Song et
al (2009)[43] and Taepavarapruk and Song (2010) [45]
which recorded a neurotransmitter regulating and neu-
roprotective effects of omega-3. They declared that
omega-3 neurotransmitter regulatory effect is through
the modulation of the quaternary structure of mem-
brane proteins and membrane fluidity, which may bene-
fit the binding of 5-HT [42]. 5-HT, in turn, stimulates
neurogenesis in both vertebrate and invertebrate species
brain cells [46,47]. Moreover, they reported that, n-3
fatty acids up-regulate levels and expressions of neuro-
trophins, and its receptors [43,48,49].
As a component of membrane phospholipids, it is
documented that the percentage of omega-3 influences
the physicochemical properties of the membrane, and
thus the function of a variety of membrane-bound pro-
teins, including dopaminergic, GABAergic, and choliner-
gic receptors in vitro [15,50,51] This could support the
significant increase in neurotransmitters in omeg-3 pro-
tected brains. Ahmada et al (2008) [52] clearly demon-
strate lower numbers of dopamine neurons in rats fed a
diet deficient in n-3 PUFAs, a treatment that has been
previously shown to reduce brain phospholipids DHA
content by roughly 45%.
The significant decrease in PE, PS and PC reported in
the present study in PPA-treated rats (table 1 and figure
2) could be easily related to brain injury of treated pups.
Although the potential key role that phospholipids may
have in neurological disorders is not fully understood,
multiple lines of evidence to date implicate the lipid
environment in the behavior of neurotransmitter sys-
tems. Decreased phospholipid PUFAs have been demon-
Figure 2 Percentage change of phosphatidylethanolamine,
phosphatidylserine and phosphatidylcholine levels in PPA-
treated and omega-3 protected groups compared to control.
Table 2 ROC analysis of the measured parameters showing, AUC, best cutoff, Sensitivity and specificity values.
Group Parameter Area under the curve Best Cutoff value Sensitivity% Specificity%
PPA Caspase3 1.000 132.17 100.0% 100.0%
IL6 0.939 133.59 88.9% 90.9%
TNF 0.434 125.49 100.0% 36.4%
GABA 1.000 93.02 100.0% 100.0%
5HT 0.978 5.80 100.0% 90.0%
DOPA 0.922 14.96 88.9% 90.0%
OMEGA Caspase3 0.872 132.17 100.0% 69.2%
IL6 0.782 133.59 100.0% 69.2%
TNF 0.923 134.50 100.0% 84.6%
GABA 0.945 98.94 100.0% 84.6%
5 HT 0.835 5.80 100.0% 76.9%
DOPA 0.308 17.41 83.3% 30.8%
PPA PE 0.980 0.1184 100.0% 92.%
PS 1.000 0.1994 100.0% 100.0%
PC 1.000 2.7743 100.0% 100.0%
OMEGA PE 0.703 0.1030 100.0% 61.5%
PS 0.725 0.1994 100.0% 69.2%
PC 0.703 2.7743 100.0% 69.2%
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zophrenic patients, which is consistent with the hypoth-
esis of myelin-related dysfunction in schizophrenia.
Membrane defects, such as those induced by decreased
PUFAs in phospholipids, can significantly alter a broad
range of membrane functions. In addition to increased
oxidative stress, altered immune function may also be
responsible for increased phospholipase activities. This
association is particularly relevant in relation to phos-
pholipids/PUFA, as AA can be converted to a variety of
Figure 3 ROC Curve of caspas3, IL6, TNF, GABA, serotonin and dopamine in PPA group.
Figure 4 ROC Curve of caspas3, IL6, TNF, GABA, serotonin and dopamine in omega-protected group.
Figure 5 ROC of phospholipids in PPA-treated group. Figure 6 ROC of phospholipids in omega-3 protected groups.
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which serve as potent messengers in regulating the
inflammatory response, as well as endocannabinoids,
which may affect brain psychopathology. Direct evidence
of immune changes in some patients with autism has
come to light, particularly in the activities of several
cytokines known to be altered in autoimmune dysfunc-
tion. Moreover PUFA are known to regulate neurodeve-
lopment, neurotransmitter homeostasis, PE signaling.
Table 2 and figures 3, 4, 5 and 6 demonstrate the
ROC analysis of the measured parameters in PPA-trea-
ted and omega-protected rats. It could be easily noted
that all the measured parameters show satisfactory
values of sensitivity and specificity in both groups. This
could help to suggest that the investigated parameters
could ascertain the neurotoxicity effect of PPA and the
effectiveness of omega-3 in ameliorating the toxic effect
of PPA.
The Pearson’s positive correlations seen in table 3 and
figure 7 between the measured phospholipids and neu-
rotransmitters (5HT, GABA and DA), and the negative
correlations observed between phospholipids and Il-6
and caspase-3 could be explained on the basis that PPA
may modulate immune function by stimulating the
release of proinflammatory cytokines as TNF-a and IL-
6. This immune system modulation or autoimmune
response could be directed against lipid membrane com-
ponents, such as phospholipids (PE, PS and PC). Disrup-
tion of brain cells membrane could easily lead to
increased efflux of neurotransmitters.
The previously explained mechanism of the protective
effect of omega-3 PUSFA could support the remarkable
improvement of most of the measured parameters in ω-
3-protected rat pups. This could help to suggest that ω-
3 supplementation could be used to ameliorate the
impairment in neurotransmitters, cytokines previously
Table 3 Pearson correlation test, demonstrating positive and negative correlations between all the measured
parameters.
Parameters R (Person Correlation) Sig.
Caspase-3 ~ IL-6 0.734 0.000 P
a
Caspase-3 ~ GABA -0.765 0.000 N
b
Caspase-3 ~ Serotonin -0.695 0.001 N
b
Caspase-3 ~ Dopamine -0.472 0.041 N
b
Caspase-3 ~ Phosphatidylethanolamine -0.641 0.002 N
b
Caspase-3 ~ Phosphatidylserine -0.797 0.000 N
b
Caspase-3 ~ Phosphatidylcholine -0.761 0.000 N
b
IL-6 ~ GABA -0.683 0.001 N
b
IL-6 ~ Serotonin -0.641 0.002 N
b
IL-6 ~ Phosphatidylethanolamine -0.585 0.007 N
b
IL-6 ~ Phosphatidylserine -0.576 0.008 N
b
IL-6 ~ Phosphatidylcholine -0.690 0.001 N
b
GABA ~ Serotonin 0.822 0.000 P
a
GABA ~ Dopamine 0.661 0.002 P
a
GABA ~ Phosphatidylethanolamine 0.737 0.000 P
a
GABA ~ Phosphatidylserine 0.839 0.000 P
a
GABA ~ Phosphatidylcholine 0.703 0.001 P
a
Serotonin ~ Dopamine 0.657 0.002 P
a
Serotonin ~ Phosphatidylethanolamine 0.829 0.000 P
a
Serotonin ~ Phosphatidylserine 0.818 0.000 P
a
Serotonin ~ Phosphatidylcholine 0.776 0.000 P
a
Dopamine ~ Phosphatidylethanolamine 0.613 0.005 P
a
Dopamine ~ Phosphatidylserine 0.679 0.001 P
a
Dopamine ~ Phosphatidylcholine 0.667 0.002 P
a
Phosphatidylethanolamine ~ Phosphatidylserine 0.879 0.000 P
a
Phosphatidylethanolamine ~ Phosphatidylcholine 0.820 0.000 P
a
Phosphatidylserine ~ Phosphatidylcholine 0.853 0.000 P
a
￿
a
. Positive Correlation.
￿
b
. Negative Correlation.
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suggestion could be supported through considering the
previous work of Santiago et al (2010) [53] and Ferraz
et al (2011) [54] that ω-3 PUFAs supplementation is
associated with increases in hippocampal serotonin and
promotes beneficial effects on anxiety, cognitive and
depressive-like behaviors in rats subjected to a restraint
stress protocol.
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